AR073548A1 - Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico - Google Patents
Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido uricoInfo
- Publication number
- AR073548A1 AR073548A1 ARP090103415A ARP090103415A AR073548A1 AR 073548 A1 AR073548 A1 AR 073548A1 AR P090103415 A ARP090103415 A AR P090103415A AR P090103415 A ARP090103415 A AR P090103415A AR 073548 A1 AR073548 A1 AR 073548A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- butyl
- cyclopropylmethyl
- propyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 3
- 229940116269 uric acid Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- -1 polymorph Chemical class 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 229910006069 SO3H Inorganic materials 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen en la presente compuestos utiles en la modulacion de los niveles de ácido urico en la sangre, formulaciones que los contienen y métodos para hacerlos y usarlos. En algunas realizaciones, un compuesto descrito en la presente se usa en el tratamiento o prevencion de enfermedades relacionadas a niveles aberrantes de ácido urico. Reivindicacion 1: Un compuesto de la formula (1) o un metabolito, sal farmacéuticamente aceptable, solvato, polimorfo, éster, tautomero o profármaco del mismo, caracterizado porque: T es N o CH; W es O, S, S(O), S(O)2, NH, N(alquilo), CH2, CH2O, CH2S o CH2NH; R1 es H, F, Cl, Br, I, -CH2F, -CF2H, -CF3, -CN, -OH, -NO2, -NH2, -NH(alquilo) , -N(alquil)(alquilo), -SO2CH3, -SO2NH2, -SO2NHCH3, -CO2-alquilo, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alcoxi opcionalmente sustituido, S-alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; a es 0, 1 o 2; Ra es H o alquilo C1-3; Ra' es H o alquilo C1-3; o Ra y Ra' junto con el átomo de carbono al cual se enlazan forman un anillo de 3, 4, 5 o 6 miembros opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; Rb, Rc, Re, y Rf son cada uno independientemente H, F, Cl, Br, I, CF3, CN, alquilo, cicloalquilo, ciclopropilmetilo, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; Rd es H, F, Cl, Br, I, CF3, CN, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; R' es metilo, etilo, n-propilo, i-propilo, n-butilo, i-butilo, s-butilo, t-butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclopropilmetilo o fenilo; R'' es metilo, etilo, n-propilo, i-propilo, n-butilo, i-butilo, s-butilo, t-butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclopropilmetilo o fenilo; R' y R'' junto con el átomo de nitrogeno al cual se enlazan forman un anillo heterocíclico de 4, 5 o 6 miembros saturado o no saturado, opcionalmente sustituido; o Rb y Rc, o Rc y Rd, o Rd y Re, o Re y Rf junto con los dos átomos de carbono a los cuales se enlazan, forman un anillo de 5, 6 o 7 miembros aromático o no aromático opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; y en donde los sustituyentes opcionales son cada uno independientemente F, Cl, Br, I, CF3, CN, alquilo, cicloalquilo, ciclopropilmetilo, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; x es 0 o 1; y es 0 o 1; z es 0 o 1; Rx, Rx', Ry, Ry', Rz y Rz' son cada uno independientemente H, F, Cl, Br, I o alquilo C1-3; o Rx y Rx', o Ry y Ry', o Rz y Rz', o Rx y Ry, o Ry y Rz, o Rx y Rz junto con los átomos de carbono a los cuales se enlazan, forman un anillo de 3-7 miembros no aromático opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; A es H, C(O)O-B1 o C(O)NH-B2; en donde B1 es H, alquilo C1-6 opcionalmente sustituido o un cation farmacéuticamente aceptable; B2 es H o alquilo C1-6 opcionalmente sustituido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9438808P | 2008-09-04 | 2008-09-04 | |
| US18011009P | 2009-05-20 | 2009-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073548A1 true AR073548A1 (es) | 2010-11-17 |
Family
ID=41726354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103415A AR073548A1 (es) | 2008-09-04 | 2009-09-04 | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8193234B2 (es) |
| EP (2) | EP2328879A4 (es) |
| JP (3) | JP2012502049A (es) |
| KR (2) | KR20110050708A (es) |
| CN (3) | CN103819419B (es) |
| AR (1) | AR073548A1 (es) |
| AU (2) | AU2009289647C1 (es) |
| BR (1) | BRPI0918586A2 (es) |
| CA (2) | CA2735828C (es) |
| EA (2) | EA201100441A1 (es) |
| IL (2) | IL211428A0 (es) |
| MX (2) | MX2011002450A (es) |
| TW (2) | TWI377200B (es) |
| WO (2) | WO2010028189A2 (es) |
| ZA (3) | ZA201101626B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604310B1 (en) | 2001-12-05 | 2018-05-02 | Keystone Heart Ltd. | Endovascular device for entrapment of particulate matter |
| US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN103819419B (zh) | 2008-09-04 | 2016-12-07 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| EP2432468A2 (en) | 2009-05-20 | 2012-03-28 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
| BR112012016795A2 (pt) * | 2010-01-08 | 2020-09-01 | Ardea Biosciences Inc. | formas polimórficas, cristalinas e de mesofase de 2-(5- bromo -4-(4-ciclopropilnaftalen-1-il)-4h-1,2,34-triazol-3iltio) acetato de sódio e seus usos |
| CA2794798C (en) | 2010-03-30 | 2017-05-30 | Ardea Biosciences, Inc. | Treatment of gout |
| LT2582683T (lt) * | 2010-06-15 | 2018-06-11 | Ardea Biosciences, Inc. | Podagros ir hiperuricemijos gydymas |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| WO2011159840A2 (en) | 2010-06-16 | 2011-12-22 | Ardea Biosciences, Inc. | Phenylthioacetate compounds, compositions and methods of use |
| ES2614914T3 (es) * | 2010-12-30 | 2017-06-02 | Ardea Biosciences, Inc. | Formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético y usos de las mismas |
| LT2714669T (lt) * | 2011-05-24 | 2017-08-10 | Ardea Biosciences, Inc. | Hipertenzija ir hiperurikemija |
| PL2776028T3 (pl) | 2011-11-03 | 2019-03-29 | Ardea Biosciences, Inc. | 3,4-di-podstawiony związek pirydynowy, sposoby jego zastosowania i zawierające go kompozycje |
| AR091651A1 (es) | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
| KR20150082194A (ko) * | 2012-11-14 | 2015-07-15 | 데이진 화-마 가부시키가이샤 | 피리딘 유도체 |
| CN103389346B (zh) * | 2013-07-18 | 2014-08-06 | 湖北华世通潜龙药业有限公司 | 利用hplc测定非布司他及口服制剂中有关物质的方法 |
| CN103588716A (zh) * | 2013-11-22 | 2014-02-19 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法 |
| JP6470761B2 (ja) * | 2013-11-22 | 2019-02-13 | クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． | レシヌラドおよびそのナトリウム塩の結晶形態 |
| CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
| CN104292178B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292177B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292176B (zh) * | 2014-10-07 | 2016-06-29 | 张远强 | 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途 |
| CN104262276B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104341367B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 一类四氮唑乙酸类化合物、其制备方法及用途 |
| CN104292175B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含硝基的四氮唑乙酸类化合物、其制备方法及用途 |
| CN104356078A (zh) * | 2014-10-27 | 2015-02-18 | 张远强 | 卤代三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326999B (zh) * | 2014-10-27 | 2017-01-18 | 张远强 | 烷氧基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326997B (zh) * | 2014-10-27 | 2016-09-21 | 张远强 | 烷氧基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104326995A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104341365A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 卤代三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104327000B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326998B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104370841B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104341364A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 三氮唑丙二酸类化合物、其制备方法及用途 |
| CN104341361B (zh) * | 2014-10-27 | 2017-01-11 | 张远强 | 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104370843B (zh) * | 2014-10-27 | 2016-05-18 | 张远强 | 卤代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104370842B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326994A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104341363B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104311498B (zh) * | 2014-10-27 | 2016-04-06 | 张远强 | 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326993B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
| CN104341362B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
| CN104326996A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途 |
| KR20170110083A (ko) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | 경피 투여를 위한 방법 및 제형 |
| US10173990B2 (en) | 2014-12-29 | 2019-01-08 | Nippon Chemiphar Co., Ltd. | URAT1 inhibitor |
| CN104817562B (zh) * | 2015-04-17 | 2017-05-03 | 东南大学 | 一种具有治疗及预防高尿酸血症或痛风的化合物及其制备方法和应用 |
| CN106187926B (zh) * | 2015-04-30 | 2018-11-27 | 天津药物研究院有限公司 | 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
| EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
| CN108026043A (zh) * | 2015-08-14 | 2018-05-11 | 广东东阳光药业有限公司 | 一种萘环化合物的晶型 |
| CA3025078C (en) * | 2016-05-23 | 2021-04-13 | Cstone Pharmaceutical (Suzhou) Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
| CN109476611B (zh) * | 2016-06-17 | 2022-08-23 | 南京明德新药研发有限公司 | 一种卤代化合物及其轴手性异构体 |
| CN107540619B (zh) | 2016-06-29 | 2019-08-16 | 天津药物研究院有限公司 | 一种尿酸转运体1抑制剂的制备方法 |
| CN107814795B (zh) * | 2016-09-12 | 2020-12-18 | 江苏艾立康药业股份有限公司 | 作为urat1抑制剂的化合物 |
| CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| CN109134391A (zh) * | 2018-09-21 | 2019-01-04 | 山东大学 | 一种酰基磺酰胺类衍生物及其制备方法与应用 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN111763218B (zh) * | 2020-07-14 | 2021-05-28 | 山东大学 | 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
| US2009A (en) * | 1841-03-18 | Improvement in machines for boring war-rockets | ||
| US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
| US4198513A (en) * | 1970-09-25 | 1980-04-15 | Merck & Co., Inc. | 1,2,4-Triazoles |
| NL7112373A (es) * | 1970-09-25 | 1972-03-28 | ||
| US4935438A (en) * | 1987-12-29 | 1990-06-19 | Smithkline Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| CA2251368A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| GB0028702D0 (en) * | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| CA2496565C (en) | 2002-08-23 | 2013-04-02 | Ribapharm Inc. | Non-nucleoside reverse transcriptase inhibitors |
| US7642277B2 (en) * | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| CN1934095A (zh) * | 2004-03-08 | 2007-03-21 | 惠氏公司 | 离子通道调节剂 |
| WO2005086895A2 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP2433633A1 (en) * | 2004-08-25 | 2012-03-28 | Ardea Biosciences, Inc. | Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase |
| WO2007050087A1 (en) * | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| WO2006091506A2 (en) * | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Neuropeptide y4 receptor agonists |
| US8063083B2 (en) * | 2006-05-25 | 2011-11-22 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| MX2010005776A (es) * | 2007-11-27 | 2010-08-31 | Ardea Biosciences Inc | Nuevos compuestos y composiciones y metodos de uso. |
| US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN103819419B (zh) * | 2008-09-04 | 2016-12-07 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| CA2761335A1 (en) | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Compounds, compositions and methods for modulating uric acid levels |
-
2009
- 2009-09-03 CN CN201410075960.4A patent/CN103819419B/zh active Active
- 2009-09-03 EP EP09812246A patent/EP2328879A4/en not_active Withdrawn
- 2009-09-03 MX MX2011002450A patent/MX2011002450A/es active IP Right Grant
- 2009-09-03 US US12/553,863 patent/US8193234B2/en not_active Expired - Fee Related
- 2009-09-03 JP JP2011526210A patent/JP2012502049A/ja active Pending
- 2009-09-03 WO PCT/US2009/055947 patent/WO2010028189A2/en not_active Ceased
- 2009-09-03 WO PCT/US2009/055948 patent/WO2010028190A2/en not_active Ceased
- 2009-09-03 EA EA201100441A patent/EA201100441A1/ru unknown
- 2009-09-03 JP JP2011526211A patent/JP2012502050A/ja active Pending
- 2009-09-03 CA CA2735828A patent/CA2735828C/en not_active Expired - Fee Related
- 2009-09-03 KR KR1020117007534A patent/KR20110050708A/ko not_active Abandoned
- 2009-09-03 KR KR1020117007535A patent/KR101294872B1/ko active Active
- 2009-09-03 EP EP09812245A patent/EP2328874A4/en not_active Withdrawn
- 2009-09-03 CN CN200980141092.2A patent/CN102186832B/zh active Active
- 2009-09-03 MX MX2011002449A patent/MX2011002449A/es active IP Right Grant
- 2009-09-03 AU AU2009289647A patent/AU2009289647C1/en active Active
- 2009-09-03 CA CA2736117A patent/CA2736117C/en active Active
- 2009-09-03 CN CN2009801411431A patent/CN102186827A/zh active Pending
- 2009-09-03 AU AU2009289646A patent/AU2009289646B2/en not_active Ceased
- 2009-09-03 BR BRPI0918586A patent/BRPI0918586A2/pt not_active Application Discontinuation
- 2009-09-03 EA EA201100440A patent/EA023500B1/ru not_active IP Right Cessation
- 2009-09-04 TW TW098130011A patent/TWI377200B/zh not_active IP Right Cessation
- 2009-09-04 AR ARP090103415A patent/AR073548A1/es unknown
- 2009-09-04 TW TW098130010A patent/TW201018463A/zh unknown
- 2009-09-04 US US12/554,737 patent/US8344012B2/en not_active Expired - Fee Related
-
2011
- 2011-02-27 IL IL211428A patent/IL211428A0/en unknown
- 2011-02-27 IL IL211429A patent/IL211429A/en active IP Right Grant
- 2011-03-02 ZA ZA2011/01626A patent/ZA201101626B/en unknown
-
2012
- 2012-05-23 ZA ZA2012/03779A patent/ZA201203779B/en unknown
- 2012-06-01 ZA ZA2012/04031A patent/ZA201204031B/en unknown
- 2012-06-04 US US13/488,191 patent/US20130040963A1/en not_active Abandoned
-
2014
- 2014-09-26 JP JP2014196668A patent/JP5918327B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073548A1 (es) | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CA2443950A1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
| RU2009127095A (ru) | Новые оксадиазольные соединения | |
| JP2012522729A5 (es) | ||
| RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| AR062427A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
| RU2011152891A (ru) | Диарилгидантоины | |
| RU2009127644A (ru) | Новые соединения | |
| JP2008525526A5 (es) | ||
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| PE20000568A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| RU2007102281A (ru) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae | |
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |